Product Information
STEGLATRO 15 MG TABLET is a brand product labeled by Merck Sharp & Dohme LLC, priced at $11.4425 per EA under NDC 00006536403. Its NADAC has been published 420 times since Sep 19, 2018.
FDA first approved this application on Dec 19, 2017.
Strength
15 mg/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006536403
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ERTUGLIFLOZIN PIDOLATEApproval Type
New Drug (NDA)
FDA Application
NDA209803FDA Approved
12/19/2017
On Market Since
12/19/2017
Price Statistics
The NADAC for STEGLATRO 15 MG TABLET has been published 420 times since Sep 19, 2018, and over the history we have for it it has risen 33.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.4425 per EA |
|---|---|
| All-time high | $11.4463 (Jun 12, 2024) |
| All-time low | $8.5638 (Sep 19, 2018) |
| 52-week high | $11.4433 |
| 52-week low | $11.4243 |
| Median price | $10.3981 |
| Average price | $10.3905 |
| Largest weekly change | +5.0% (Jan 18, 2023) |
| Weeks tracked | 420 |
| Tracking since | Sep 19, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Merck Sharp & Dohme LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ertugliflozin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of STEGLATRO 15 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for STEGLATRO 15 MG TABLET, manufactured by Merck Sharp & Dohme LLC, is $11.4425 per EA (NDC 00006536403), effective Sep 30, 2026.
How has the price of STEGLATRO 15 MG TABLET changed over time?
Over the history we have for it, the NADAC for STEGLATRO 15 MG TABLET has risen 33.6%. It has been tracked across 420 weekly CMS publications since Sep 19, 2018.
What are the highest and lowest recorded NADAC prices for STEGLATRO 15 MG TABLET?
Since Sep 19, 2018, the NADAC for STEGLATRO 15 MG TABLET has ranged from a low of $8.5638 (Sep 19, 2018) to a high of $11.4463 (Jun 12, 2024), with a median of $10.3981 per EA.
Are there cheaper alternatives to STEGLATRO 15 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, STEGLATRO 15 MG TABLET, is $10.9171 per EA — about 5% below STEGLATRO 15 MG TABLET.
Who manufactures STEGLATRO 15 MG TABLET?
STEGLATRO 15 MG TABLET (NDC 00006536403) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.